Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Lung Cancer

Free Subscription 22.12.2025 1 Am J Clin Oncol 2 Ann Oncol 4 BMC Cancer 2 Cancer 2 Cancer Lett 5 Cancer Res 1 Cancer Sci 2 Clin Cancer Res 1 Clin Lung Cancer 1 Clin Nucl Med 1 Eur J Cancer 2 Eur J Cardiothorac Surg 3 Int J Cancer 1 Int J Radiat Oncol Biol Phys 2 J Clin Invest 3 J Clin Oncol 1 Lung Cancer 1 Lung Cancer (Auckl) 1 Nat Med 1 Oncogene 4 PLoS One 1 Thorax

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. ABDELMONEM A, Bikram Shah B, Shebli MA, Tabbara IA, et al
   Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.
   Am J Clin Oncol. 2025 Dec 15. doi: 10.1097/COC.0000000000001275.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. GOVINDAN R, Navo K, Huang M, Liu J, et al
   Germline alterations in patients with lung cancer.
   Ann Oncol. 2025 Dec 16:S0923-7534(25)06328-8. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   
3. ALDEA M, Zullo L, Levrat V, Bennouna J, et al
   Next-Generation Multicenter Studies: Using Artificial Intelligence to Automatically Process Unstructured Health Records of Patients with Lung Cancer across Multiple Institutions.
   Ann Oncol. 2025 Dec 15:S0923-7534(25)06320-3. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. YANG H, Han Y, Zhou X, Li J, et al
   The incidence and risk factors of pulmonary infection complications in lung cancer patients treated with immune checkpoint inhibitors.
   BMC Cancer. 2025;25:1871.
   PubMed         Abstract available
   
   
5. YANO R, Tokito T, Murotani K, Murata D, et al
   Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer.
   BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15467.
   PubMed        
   
   
6. OI I, Fujita K, Imakita T, Okada Y, et al
   Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study.
   BMC Cancer. 2025 Dec 19. doi: 10.1186/s12885-025-15479.
   PubMed         Abstract available
   
   
7. SAHRAI H, Behnood J, Baradaran M, Khalaji A, et al
   Diagnostic accuracy of CT-based radiomics models in differentiating lung cancer from tuberculosis in pulmonary lesions: a systematic review and meta-analysis.
   BMC Cancer. 2025 Dec 17. doi: 10.1186/s12885-025-15446.
   PubMed        
   
   

   
   Cancer

8. ZHANG P, Wang D, Yin S, Dong Y, et al
   Magnetic resonance-guided split-course hypo-fractionated radiotherapy with concurrent chemotherapy and consolidative immunotherapy in locally advanced non-small cell lung cancer: A single arm, phase 2 study.
   Cancer. 2025;131:e70223.
   PubMed         Abstract available
   
   
9. RITZWOLLER DP, Carroll NM, Wain KF, Hixon BP, et al
   Examining trends in lung cancer screening over 10 years: Eligibility, participation, cancer detection, and quality implications.
   Cancer. 2025;131:e70211.
   PubMed         Abstract available
   
   

   
   Cancer Lett

10. WU F, Shen J, Zhao Z, Chen Y, et al
    HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8(+) T cell glutamine metabolism via KIR3DL3 interaction.
    Cancer Lett. 2025;639:218219.
    PubMed         Abstract available
    
    
11. MENG X, Bi N, Wang J, Meng X, et al
    Consensus on the Diagnosis and Treatment of Unresectable Stage III Driver Gene-Positive Non-Small Cell Lung Cancer.
    Cancer Lett. 2025 Dec 17:218223. doi: 10.1016/j.canlet.2025.218223.
    PubMed         Abstract available
    
    

    
    Cancer Res

12. PRABHAKARAN S, Gatenbee CD, Robertson-Tessi M, Gahramanli Ozturk Z, et al
    Distinct Tumor-Immune Ecologies in Lung Cancer Patients Predict Progression and Define a Clinical Biomarker of Therapy Response.
    Cancer Res. 2025 Dec 19. doi: 10.1158/0008-5472.CAN-25-1594.
    PubMed         Abstract available
    
    
13. BOETTIGER K, Kovacs I, Horvath L, Ernhofer B, et al
    Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments.
    Cancer Res. 2025 Dec 18. doi: 10.1158/0008-5472.CAN-25-1483.
    PubMed         Abstract available
    
    
14. LUO H, Guo W, Luan X, Yue T, et al
    Large-Scale T-cell Receptor Repertoire Profiling Unveils Tumor-Specific Signals for Diagnosing Indeterminate Pulmonary Nodules.
    Cancer Res. 2025;85:5141-5160.
    PubMed         Abstract available
    
    
15. HAYKAL T, Yang R, Tohme C, He Z, et al
    Surgery-Induced Neutrophil Extracellular Traps Promote Tumor Metastasis by Reprogramming Cancer Cell Lipid Metabolism.
    Cancer Res. 2025;85:4995-5014.
    PubMed         Abstract available
    
    
16. AVELLINO A, Jiang X, Lee M, Yu J, et al
    An Olive Oil-Based High-Fat Diet Promotes Obesity-Driven Metastasis of Triple-Negative Breast Cancer.
    Cancer Res. 2025 Sep 5. doi: 10.1158/0008-5472.CAN-25-0822.
    PubMed         Abstract available
    
    

    
    Cancer Sci

17. OKADA M, Sugawara S, Watanabe Y, Saito H, et al
    IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
    Cancer Sci. 2025 Dec 19. doi: 10.1111/cas.70297.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

18. ARMSTRONG AJ, Dietz H, Balli D, Geese WJ, et al
    LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial.
    Clin Cancer Res. 2025;31:5198-5210.
    PubMed         Abstract available
    
    
19. JOHN F, Ruge L, Verheyen M, Scharpenseel H, et al
    Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS G12V mutations.
    Clin Cancer Res. 2025 Dec 19. doi: 10.1158/1078-0432.CCR-25-2581.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

20. WANG H, Sun W, Wang C, Yang X, et al
    A Comprehensive Analysis of HER2 status Heterogeneity Using Matched Samples among Potential Beneficiaries of Trastuzumab Deruxtecan Therapy in Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Nov 21:S1525-7304(25)00323.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

21. XIANG J, Yan Y, Zhang Z, Zhang L, et al
    Complementary Role of [68Ga]Ga-DOTA-3P-TATE-RGD PET/CT in Discriminating Non-Small Cell From Small Cell Lung Cancer.
    Clin Nucl Med. 2025 Dec 15. doi: 10.1097/RLU.0000000000006258.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

22. NGUYEN VT, Binoy R, Kalofonou F, Davidson M, et al
    Review and comment on the retrospective analyses of the effect of immunotherapy-infusion time of day on outcome in patients with advanced non-small cell lung cancer.
    Eur J Cancer. 2025;233:116171.
    PubMed        
    
    

    
    Eur J Cardiothorac Surg

23. KUZDZAL J, Zhang L, Turna A, Szadurski J, et al
    Randomized study on bilateral vs standard mediastinal lymphadenectomy in patients with lung cancer-early results and safety analysis.
    Eur J Cardiothorac Surg. 2025 Dec 18:ezaf457. doi: 10.1093.
    PubMed         Abstract available
    
    
24. BRASCIA D, Mehta Warikoo I, Mangiameli G, Luppichini M, et al
    Long-term oncological outcomes and recurrence patterns after segmentectomy for early-stage non-small cell lung cancer: A dual-center retrospective study.
    Eur J Cardiothorac Surg. 2025 Dec 14:ezaf449. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

25. XU M, Xu Y, Man Y, Xiang X, et al
    Real-world effectiveness and safety of treatment strategies for unresectable, driver-negative Stage III NSCLC: A retrospective multicentre study.
    Int J Cancer. 2026;158:1042-1054.
    PubMed         Abstract available
    
    
26. NEOGI U, Ambikan AT, Turkowski K, Schneider MA, et al
    Plasma proteomic profiling and molecular clustering reveal immune-defined prognostic subtypes in lung adenocarcinoma.
    Int J Cancer. 2026;158:858-865.
    PubMed         Abstract available
    
    
27. WU YS, Kunst N, Gyorbiro DM, Kristiansen IS, et al
    Cost-effectiveness of low-dose CT lung cancer screening among individuals that have ever smoked in Norway: A model-based analysis using NELSON trial criteria and outcomes.
    Int J Cancer. 2025 Dec 19. doi: 10.1002/ijc.70270.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

28. SIMONE CB 2ND
    A Potential Path Toward Finally Improving Outcomes With Concurrent Immunotherapy and Chemoradiation for Lung Cancer: Low-Dose Radiation Therapy Lessons From the MATCH Trial in Extensive-Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2026;124:174-176.
    PubMed        
    
    

    
    J Clin Invest

29. DRAGONI F, Sop J, Gurumurthy I, Beckey TP, et al
    Selective targeting of HIV infected clones by cognate peptide stimulation and antiproliferative drugs.
    J Clin Invest. 2025 Oct 21:e197266. doi: 10.1172/JCI197266.
    PubMed         Abstract available
    
    
30. QIU Z, Song NJ, Li A, Singh D, et al
    PPP2R2A insufficiency enhances PD-L1 immune checkpoint blockade efficacy in lung cancer through cGAS-STING activation.
    J Clin Invest. 2025 Dec 18:e193354. doi: 10.1172/JCI193354.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

31. DIX DB, Khanna G, Renfro LA, Tfirn IC, et al
    Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533.
    J Clin Oncol. 2025;43:3822-3832.
    PubMed         Abstract available
    
    
32. YAO W, Zhou Q, Shi T, Xu L, et al
    Blind Spots in REZILIENT-1: Does Post-Platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Dec 17:JCO2501501. doi: 10.1200/JCO-25-01501.
    PubMed        
    
    
33. PIOTROWSKA Z, Yu HA
    Reply to: Blind Spots in REZILIENT-1: Does Post-platinum Zipalertinib Address Needs in Epidermal Growth Factor Receptor ex20ins+ Non-Small Cell Lung Cancer?
    J Clin Oncol. 2025 Dec 17:JCO2502185. doi: 10.1200/JCO-25-02185.
    PubMed        
    
    

    
    Lung Cancer

34. PHILLIPS WJ, Zhan LJ, Chowdhury D, Gill J, et al
    Corrigendum to "Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)" [Lung Cancer 210 (2025) 108840].
    Lung Cancer. 2025 Dec 16:108875. doi: 10.1016/j.lungcan.2025.108875.
    PubMed        
    
    

    
    Lung Cancer (Auckl)

35. SCHNEIDER GALVAO G, Favero Prietto Dos Santos J, Hsu YR, Rogalla P, et al
    Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker.
    Lung Cancer (Auckl). 2025;16:161-166.
    PubMed         Abstract available
    
    

    
    Nat Med

36. REUSS JE, Lee PK, Mehran RJ, Hu C, et al
    Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.
    Nat Med. 2025;31:4097-4108.
    PubMed         Abstract available
    
    

    
    Oncogene

37. LUO J, Xu X, Chen Y, Huang Y, et al
    YTHDC2 inhibits the resistance of lung cancer to EGFR-TKI through cuproptosis.
    Oncogene. 2025 Dec 16. doi: 10.1038/s41388-025-03660.
    PubMed         Abstract available
    
    

    
    PLoS One

38. LI J, Shen Z, Liu D, Ma J, et al
    A novel prognostic model for lung squamous cell carcinoma based on multi-omics analysis and machine learning.
    PLoS One. 2025;20:e0336792.
    PubMed         Abstract available
    
    
39. WEI S, Zhang L, Liu C, Qi X, et al
    Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System.
    PLoS One. 2025;20:e0339005.
    PubMed         Abstract available
    
    
40. YANG Y, Zhao B, Jiang Y, Han X, et al
    Overexpression of PTPRCAP inhibits biological function of lung adenocarcinoma through apoptosis pathway.
    PLoS One. 2025;20:e0337223.
    PubMed         Abstract available
    
    
41. EL-TANANI M, Satyam SM, Rabbani SA, El-Tanani Y, et al
    Disruption of epidermal growth factor receptor signaling and cytoskeletal dynamics by mebendazole and gefitinib synergistically impairs paracrine cytokine signaling in non-small cell lung cancer and triple-negative breast cancer Cell lines.
    PLoS One. 2025;20:e0338027.
    PubMed         Abstract available
    
    

    
    Thorax

42. MIYAKE K, Oki M, Suzuki H, Saka H, et al
    Balloon dilatation for bronchoscope delivery: first-in-human trial of a novel technique for peripheral lung field access.
    Thorax. 2025;81:33-41.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.